Last reviewed · How we verify
Mesenchymoangioblast-derived mesenchymal stem cells
At a glance
| Generic name | Mesenchymoangioblast-derived mesenchymal stem cells |
|---|---|
| Also known as | CYP-001 |
| Sponsor | Cynata Therapeutics Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Efficacy of CYP-006TK in Adults with Diabetic Foot Ulcers (PHASE1)
- The MEseNchymal coviD-19 Trial: MSCs in Adults With Respiratory Failure Due to COVID-19 or Another Underlying Cause (PHASE1)
- A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: